At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,168 enrolled
Drug / intervention
botulinum toxin Type Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BOTOX® Prophylaxis in Patients With Chronic Migraine
In Brief
An observational study evaluating botulinum toxin Type A for Migraine Disorders. Completed, enrolled 1,168 participants across 4 sites in 4 countries.
Detailed Summary
This is a post authorization observational study to monitor the utilization practices and describe the safety profile of BOTOX® in clinical practice for the prophylactic treatment of headaches in adult patients with chronic migraine.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
CountriesGermany, Spain, Sweden, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
First PostedSep 2011
Primary CompletionMay 2015
TodayJul 2026
First PostedSep 13, 2011
Enrollment StartSep 9, 2011
Primary CompletionMay 12, 2015
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 14.8 years ago
Interventions
botulinum toxin Type Abiological
155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.